Grok comparison of Fisetin and D+Q

#3

Another run at the same question… this time using Gemini Pro and a tweaked prompt I use for analyzing research papers and claims, Thinking mode. Human equivalent doses included:

Gemini Pro response.

A paradigm shift is underway in longevity science: the move from “maintenance” (antioxidants) to “demolition” (senolytics). For years, the gold standard for clearing senescent “zombie” cells—dysfunctional cells that refuse to die and poison their neighbors—has been the pharmaceutical cocktail of Dasatinib plus Quercetin (D+Q). While effective, Dasatinib is a toxic leukemia drug with significant baggage. Now, a natural flavonoid derived from strawberries, Fisetin, has emerged as a safer, “hit-and-run” alternative that may rival the heavyweight champion without the prescription-grade toxicity.

The “Big Idea” here is the rigorous validation of intermittent dosing. Unlike supplements taken daily, senolytics are designed to be taken in short, high-dose bursts (e.g., two days a month) to shock the system, clear the accumulated cellular debris, and then step back to allow tissue regeneration. This research confirms that Fisetin, when used in this specific “shock” protocol, selectively induces apoptosis (programmed cell death) in senescent cells while leaving healthy tissue unharmed.

However, recent comparative data suggests a nuance: while Fisetin is the “safest” broad-spectrum senolytic, it may lack the aggressive tissue-penetrating power of D+Q for specific deep-tissue pathologies like neurodegeneration or fibrosis. The race is no longer just about finding a senolytic, but about matching the weapon (Fisetin vs. D+Q) to the target (frailty vs. severe organ damage).

Part 2: The Biohacker Analysis (Style: Technical, Academic, Direct)

Study Design Specifications

  • Type: Pre-clinical (Murine) & Human Ex Vivo validation; Comparative analysis with Clinical Trial Protocols.
  • Subjects:
    • Murine: C57BL/6 wild-type mice (progeroid Ercc1-/Δ models and naturally aged 22-24 month old mice). Sex: Both Male and Female.
    • Human Validation: Adipose tissue explants from obese human subjects.
  • Protocol (Fisetin): Intermittent “Hit-and-Run.”
    • Mouse: 100 mg/kg oral gavage for 5 consecutive days, or intermittent weekly cycles.
    • Control: Vehicle-treated age-matched controls.

Lifespan Analysis

  • Extension: In the seminal EBioMedicine study, late-life intervention (starting at 85 weeks, approx. 20 months) extended median lifespan by ~10% and maximum lifespan by ~5-15% compared to controls.
  • Context: These gains are modest compared to Rapamycin (often 15-25%), but significant because the intervention began late in life—equivalent to a human starting treatment at age 60-70.
  • Control Validation: The control lifespans in these studies align with standard C57BL/6 historical data (~900 days median), validating that the treatment effect wasn’t due to weak controls.

Mechanistic Deep Dive

  • Target: SCAP Network (Senescent Cell Anti-Apoptotic Pathways). Senescent cells survive by upregulating pro-survival factors (BCL-2, BCL-xL, PI3K/AKT) to resist their own inflammatory signals.
  • Fisetin Action: Acts as a natural caloric restriction mimetic and PI3K/AKT/mTOR inhibitor. It lowers p16^Ink4a^ and p21^Cip1^ expression specifically in adipose and immune lineages.
  • D+Q Action: Dasatinib inhibits Src kinase (broad spectrum), while Quercetin targets BCL-2. Together, they cover a wider range of senescent cell types (SCAPs) than either alone, which explains D+Q’s superior potency in fibrotic tissue and bone.
  • Organ Specificity: Fisetin shines in visceral adipose tissue (reducing inflammation/frailty) and immune function. D+Q appears superior for vascular and neuronal clearance (e.g., clearing tau-associated senescence in Alzheimer’s models).

Novelty & Critical Limitations

  • Novelty: The demonstration that a single natural compound (Fisetin) could effectively reduce senescent burden in humans (adipose tissue) without the side-effect profile of tyrosine kinase inhibitors (Dasatinib).
  • Critical Limitations:
    • Translational Gap: The 100 mg/kg mouse dose is massive. Achieving similar tissue concentrations in humans requires liposomal formulations or extremely high oral doses (20 mg/kg), which leads to unknown long-term stress on the liver/kidneys.
    • Efficacy Ceiling: In direct head-to-head comparisons (e.g., Alzheimer’s models), Fisetin sometimes fails where D+Q succeeds Senolytic intervention improves cognition (2025). Fisetin may be too weak for severe, established pathology.
    • Bioavailability: Standard Fisetin has dismal oral bioavailability due to rapid Phase II metabolism (sulfation/glucuronidation).

Part 3: Claims & Verification

Claim 1: Fisetin selectively induces apoptosis in senescent cells (Senolysis) and extends lifespan.

Claim 2: The Dasatinib + Quercetin (D+Q) combination clears senescent cells in humans.

  • Verification: Confirmed in clinical trials for diabetic kidney disease and idiopathic pulmonary fibrosis.
  • Hierarchy: Level B (Open-label Clinical Trials).
  • Status: Senolytics decrease senescent cells in humans (2019)
  • Safety Note: Dasatinib has a boxed warning for pulmonary hypertension and fluid retention.

Claim 3: Fisetin reduces frailty and inflammation markers (IL-6, hsCRP).

Part 4: Actionable Intelligence (The Protocol)

Warning: The following contains analysis of research chemicals and off-label protocols. This is for informational analysis only, not medical advice. Safety data is largely absent for long-term intermittent use in humans.

1. The Translational Protocol (Rigorous Extrapolation)

A. Fisetin Protocol (The “Mayo” Approach)

  • Target: General frailty, adipose inflammation, “health maintenance.”
  • Mouse Dose: 100 mg/kg.
  • HED Calculation (Conservative BSA):

    • 100 mg/kg×(3/37)≈8.1 mg/kg

    • For a 75kg Male: ≈600 mg.

  • The Clinical Reality (Aggressive): The Mayo Clinic trials use 20 mg/kg, which is ~2.5x the BSA-calculated dose.
    • Protocol: ~1,400–1,600 mg (for 75kg human) taken orally for 2 consecutive days.
    • Frequency: Repeated once every 30 days.
    • Bioavailability Hack: Consumption with fats (yogurt/olive oil) or use of Liposomal formulations is widely recommended by biohackers to bridge the bioavailability gap, though clinical trials use standard oral powder.

B. Q+D Protocol (The “Heavy Hitter”)

  • Target: Fibrosis, severe metabolic dysfunction, potential neurodegeneration.
  • Standard Trial Dose:
    • Dasatinib: 100 mg (Prescription Only - Oncology).
    • Quercetin: 1,000 mg (Phytosome/Liposomal preferred for absorption).
  • Frequency: Dosed for 3 consecutive days, repeat every 2 weeks or monthly (protocols vary).
  • Cost-Benefit: Dasatinib is expensive and risky. The ROI is only justified for significant pathology, not general “anti-aging.”

2. Safety & Toxicity Check

  • Fisetin:
    • Safety Profile: Excellent. No dose-limiting toxicity observed in mice even at high doses.
    • Data Gap: Long-term effects of “mega-dosing” (1.5g+) on the human liver are unverified.
  • Dasatinib (D+Q):
    • Known Risks: Fluid retention (pleural effusion), QT prolongation, myelosuppression.
    • Monitoring: Requires CBC and metabolic panel monitoring if used repeatedly. NOT a casual supplement.

3. Biomarker Verification Panel

  • Don’t fly blind. If attempting these protocols, monitor:
    • SASP Factors: IL-6, TNF-alpha, hs-CRP (Should decrease post-cycle).
    • Toxicity: ALT/AST (Liver), Cystatin C (Kidney), CBC (for Dasatinib myelosuppression).

Part 5: The Strategic FAQ

1. Q: Can I just take Fisetin every day like a multivitamin? A: No. The science supports “hit-and-run.” Continuous suppression of senescent cells/SCAP networks may interfere with wound healing and immune signaling. The goal is a pulse to induce apoptosis, then a pause to regenerate. Daily low doses likely fail to reach the threshold to kill senescent cells and may just act as a weak antioxidant.

2. Q: Can I stack Rapamycin with Fisetin? A: Theoretically, yes. Rapamycin inhibits mTOR (slowing geroconversion), while Fisetin clears cells that have already become senescent. Many biohackers cycle them: Rapamycin weekly, Fisetin monthly. However, no clinical trial has validated this “stack” for safety yet.

3. Q: Is Liposomal Fisetin actually better? A: Likely. Fisetin is hydrophobic and rapidly metabolized. Liposomal delivery bypasses first-pass metabolism. If using standard powder, the Mayo dose (20 mg/kg) is necessary to force enough into the blood. If using true Liposomal, a lower dose might suffice, but we lack conversion data.

4. Q: Why not just use Quercetin alone? A: It’s too weak. Research shows Quercetin targets some SCAP pathways (BCL-2) but misses others. It works synergistically with Dasatinib but is a poor senolytic on its own compared to Fisetin.

5. Q: How do I know if it’s working? A: Subjective: Reduced joint pain, “lighter” feeling, improved endurance. Objective: Lower hs-CRP and reduced “biological age” on methylation clocks (though clock data is noisy/mixed).

6. Q: Does Fisetin cross the blood-brain barrier? A: Yes. It is neuroprotective and has shown efficacy in reducing cognitive deficits in mice, though recent data suggests D+Q might be stronger for specific Alzheimer’s pathologies (tau clearance).

7. Q: Should I fast while taking senolytics? A: Plausible. Fasting inhibits mTOR and induces autophagy, potentially sensitizing senescent cells to apoptosis. Many protocols recommend taking the senolytics in a fasted state or with a pure fat source (for absorption) without protein/carbs.

8. Q: Are there contraindications? A: Blood Thinners. Fisetin and Quercetin have mild anti-coagulant properties. High doses could increase bleeding risk if combined with Warfarin/Aspirin.

9. Q: What is the biggest “known unknown”? A: Long-term tissue depletion. We don’t know if clearing senescent cells repeatedly over 10 years eventually depletes the stem cell pool (exhaustion) or if the “space” is filled by fibrosis instead of healthy tissue in older humans.

1 Like
#4

And, for those who are seriously considering either of these approaches, I would recommend reading this Google Gemini Deep Search report on the topic:

Senolytic Interventions in Geroscience (2021–2026): A Comprehensive Review of Fisetin and Dasatinib Plus Quercetin

Executive Summary

The pursuit of interventions to delay aging and extend healthspan has coalesced around the “senolytic hypothesis”—the premise that the selective elimination of senescent cells (SnCs) can ameliorate age-related tissue dysfunction. Over the reporting period of 2021 to 2026, the field has transitioned from broad preclinical optimism to a phase of rigorous scrutiny, characterized by divergent outcomes in high-fidelity animal models and the initiation of pivotal human clinical trials. This report provides an exhaustive analysis of the scientific and clinical landscape regarding the two primary senolytic candidates: the flavonoid Fisetin and the combination therapy of the tyrosine kinase inhibitor Dasatinib plus the flavonoid Quercetin (D+Q).

The past five years have yielded a complex dichotomy in results. While the senolytic combination D+Q remains the most potent intervention for clearing senescent burden in specific pathological contexts—such as idiopathic pulmonary fibrosis (IPF) and Alzheimer’s disease—it faces intensifying safety scrutiny following 2025 reports of exacerbated renal damage in acute injury models. Conversely, Fisetin has emerged as a safer, albeit dose-sensitive, alternative. A landmark 2024 study by the National Institute on Aging’s Interventions Testing Program (ITP) demonstrated that chronic dietary administration of Fisetin failed to extend lifespan in genetically heterogeneous mice, contradicting earlier gavage-based studies. This failure has catalyzed a paradigm shift toward “hit-and-run” pulsed dosing protocols, which are now the standard in ongoing human trials like AFFIRM-LITE.

Crucially, this period saw the validation of Fisetin in preventing atrial fibrillation in aged lagomorph models (2026), providing some of the strongest organ-specific efficacy data to date. Concurrently, the definition of success in human trials has evolved from vague “anti-aging” metrics to precise biomarkers, specifically the quantification of p16 {Ink4a} variant 5 in T-cells and the modulation of the Senescence-Associated Secretory Phenotype (SASP).

This document synthesizes data from molecular mechanisms to clinical outcomes, offering a granular comparison of efficacy, safety profiles, and translational dosing protocols. It serves as a definitive reference for interpreting the disparate findings of the last half-decade and guiding future therapeutic strategies.

Google Deep Search Full report: https://gemini.google.com/share/e22c29aaf37a

#5

Lara, I was loosely following the Mayo fisetin protocol (a 20 mg dose per kg body weight, three days in a row, each month for five months). RapAdmin’s Gemini response is a little different, but ballpark is probably the best we can do at this point.

1 Like
#6

Grok doesn’t think it’s worth considering: “No, there is no evidence from current research that repeatedly clearing senescent cells over 10 years using the described Mayo fisetin protocol (approximately 20 mg/kg body weight for three consecutive days each month for five months, though protocols vary slightly in trials) would deplete the stem cell pool or cause stem cell exhaustion in older humans. In fact, the available data point in the opposite direction: senolytic interventions like fisetin tend to preserve or restore stem cell function by removing the harmful effects of senescent cells and their senescence-associated secretory phenotype (SASP), which otherwise impair stem cell niches through chronic inflammation, disrupted tissue homeostasis, and inhibited regeneration.”

Dueling AIs. It’s like robot boxers. I’ll stop now.

1 Like
#7

Just to chime in, I looked at this same comparison with ChatGPT about 2 months ago and got very similar results/conclusions. I started Fisetin using the Mayo Protocol based on my analysis.

1 Like
#8

RapAdmin, Did your analysis with Gemini Pro take into account that there are no completed human trials with Fisetin at this time, but several completed trials with D + Q even though they did have small numbers of participants? Not that this is important since there seem to be a fair number of mouse trials of each, but I am curious. As usual I’m getting my data from ChatGPT which means it could be wrong.

#9

argonaut, Have I got it right: you’re taking somewhere between a gram to a gram and a half 3 days in a row 5 months in a row? Please correct any mistakes and let me know how you take it, with food or without, etc. Then, if you can, have you noticed any type of improvement with this treatment? Thanks.

#10

See here, from this document: https://gemini.google.com/share/e22c29aaf37a

4. Preclinical Efficacy: The Animal Data (2021–2026)

The last five years of animal research have provided critical, sometimes contradictory, insights. The distinction between “lifespan extension” and “healthspan improvement” has become stark, with Fisetin showing limits in the former but excellence in the latter.

4.1 Lifespan Studies: The ITP Controversy (2024)

The most consequential publication in this period is the 2024 report from the National Institute on Aging’s Interventions Testing Program (ITP), authored by Harrison et al…

Study Overview:

The ITP is considered the gold standard for longevity research due to its use of genetically heterogeneous mice (UM-HET3), large sample sizes, and multi-site replication (Jackson Laboratory, University of Michigan, UT Health Science Center).

  • Protocol: Mice were fed a diet containing 600 ppm (parts per million) of Fisetin starting at 20 months of age (roughly equivalent to 60-year-old humans).
  • Results: Fisetin failed to extend median or maximum lifespan significantly in either male or female mice. This stood in contrast to other agents tested in the same cohort, such as Astaxanthin (12% extension in males) and Meclizine (8% extension in males).

The “Dosing Paradox”: This result contradicts the seminal 2018 study by Yousefzadeh et al., which reported significant lifespan extension in C57BL/6 mice. The discrepancy is widely attributed to the dosing method:

  • Yousefzadeh (2018): Used intermittent oral gavage (100 mg/kg daily for 5 days, repeated periodically). This creates a high peak plasma concentration ($C_{max}$) necessary to breach the apoptotic threshold of senescent cells.
  • ITP (2024): Used continuous dietary admixture. While the cumulative dose might be similar, the steady-state plasma levels likely never spiked high enough to trigger senolysis.
  • Implication: Fisetin functions as a threshold-dependent senolytic. Continuous low-level intake (as in the ITP) likely acts only as a weak antioxidant. For lifespan extension via senolysis, pulse dosing is mandatory.

4.2 Cardiac Aging: The Atrial Fibrillation Breakthrough (2026)

While systemic lifespan data is mixed, organ-specific efficacy is robust. In January 2026, Sengun et al. published a pivotal study in the Journal of the American College of Cardiology (inferred context) or similar high-impact cardiovascular journal, using an aged rabbit model.

Rationale:

Rabbits possess cardiac electrophysiology (action potential duration, ionic currents) that is far more similar to humans than murine models, making them an ideal translational model for atrial fibrillation (AF).

Key Findings:

  • Senescence in AF: The study confirmed that senescent fibroblasts accumulate in the left atrium of aged hearts, contributing to fibrosis and conduction heterogeneity.
  • Intervention: Aged rabbits received oral Fisetin (20 mg/kg) for two cycles (2 days/week).
  • Outcomes:
    • Spontaneous AF: 0% of Fisetin-treated rabbits developed spontaneous AF, compared to 40% of vehicle-treated aged controls.
    • Inducible AF: Upon electrical stimulation, only 20% of Fisetin-treated rabbits sustained AF, compared to 100% of controls.
  • Mechanism: Fisetin selectively eliminated $p16^{+}$/$\beta$-gal$^{+}$ fibroblasts, reducing atrial fibrosis and normalizing conduction velocity. This study is a cornerstone for the cardiological application of senolytics.

4.3 Renal Systems: The Acute vs. Chronic Paradox (2025)

A 2025 study by Battaglia-Vieni et al. introduced a critical safety warning regarding D+Q in renal pathology.

The Study:

Researchers utilized a Folic Acid Nephropathy (FAN) model to induce Acute Kidney Injury (AKI) in mice, treating them with D+Q.

  • Hypothesis: Clearing senescent cells would reduce inflammation and improve recovery.
  • Result: D+Q treatment worsened kidney damage. It failed to reduce p21-positive cells and increased the expression of injury markers Lcn2 (Lipocalin-2) and Havcr1 (KIM-1).
  • Interpretation: In the context of acute injury, cellular senescence is a programmed, beneficial response that limits fibrosis and coordinates repair. Prematurely clearing these cells disrupts the healing orchestrations. This contrasts with chronic kidney disease (CKD), where long-term senescence is deleterious. This finding establishes a major contraindication: Senolytics should not be administered during acute organ injury or immediate post-operative recovery.

4.4 Comparative Preclinical Efficacy Table

Feature Fisetin Dasatinib + Quercetin (D+Q)
Lifespan (Mice) Failure (Dietary, ITP 2024) Success (Injection, Mayo 2018)
Cognitive (Alzheimer’s) Improved cognition, reduced neuroinflammation; outperformed D+Q in some genotypes Reduced tau pathology and neuroinflammation; blood-brain barrier penetration varies
Cardiac (Fibrosis/AF) Highly effective in Rabbit AF model (2026); reduces fibrosis Effective in reducing vascular stiffness; risk of cardiotoxicity (QT prolongation)
Renal (Acute Injury) Generally protective (antioxidant effects dominant) Harmful; exacerbates acute injury markers (Lcn2, Havcr1)
Bone (Osteoporosis) Preserves osteoprogenitor pool; reduces bone loss in progeroid mice Increases bone density in aged mice; effective osteoclast suppression

5. Clinical Translation: Human Trials and Outcomes

The transition from animal models to human application is currently in Phase 2 clinical trials. The focus has shifted from general “anti-aging” to specific indications like frailty, kidney disease, and Alzheimer’s.

5.1 The AFFIRM-LITE Trial (Mayo Clinic)

The Alleviation by Fisetin of Frailty, Inflammation, and Related Measures (AFFIRM-LITE) trial (NCT03675724) represents the definitive test of the “Mayo Protocol” for Fisetin.

Study Design:

  • Phase: Phase 2, Randomized, Double-Blind, Placebo-Controlled.
  • Population: Older women (postmenopausal) and frail elderly adults.
  • Intervention: Oral Fisetin.
  • Protocol: 20 mg/kg/day for 2 consecutive days.
  • Rationale: This high dose (approx. 1,400–1,600 mg for an average adult) is designed to overcome poor bioavailability and achieve the serum $C_{max}$ necessary for senolysis, mimicking the successful gavage protocols in mice.

Endpoints:

  • Primary: Markers of inflammation (IL-6, TNF-$\alpha$, hsCRP) and bone resorption (CTX).
  • Secondary: Frailty markers (gait speed, grip strength), insulin resistance, and renal function.
  • Status (2025): The trial is active/ongoing. Preliminary data or parallel pilot studies suggest the protocol is safe, with no severe adverse events reported.

5.2 Diabetic Kidney Disease (D+Q)

A landmark Phase 1/2a trial tested D+Q in patients with Diabetic Kidney Disease (DKD).

  • Protocol: Dasatinib (100 mg) + Quercetin (1000 mg) for 3 days.
  • Findings: The treatment significantly reduced senescent cell burden in adipose tissue (p16+ and SA-$\beta$-gal+ cells) and decreased circulating SASP factors (IL-1$\alpha$, IL-6, MMPs).
  • Significance: This was the first proof-of-concept in humans demonstrating that senolytics can effectively clear senescent cells from tissue and reduce systemic inflammatory burden. It validated the “hit-and-run” efficacy in humans.

5.3 Alzheimer’s Disease and Cognition (ALF / ALSENLITE)

Multiple trials (e.g., ALSENLITE, SToMP-AD) are evaluating D+Q and Fisetin for mild cognitive impairment (MCI) and early Alzheimer’s.

  • D+Q Findings (2025): A small trial indicated that D+Q crosses the blood-brain barrier sufficiently to modulate tau levels and inflammation in CSF. Preliminary results hinted at functional benefits (MoCA scores) correlated with reductions in TNF-$\alpha$.
  • Fisetin Findings: Trials are recruiting. Preclinical data suggests Fisetin may be superior in preserving cognitive function due to broader neuroprotective (non-senolytic) properties, such as maintaining synaptic plasticity via the CREB-BDNF pathway.

5.4 Safety and Adverse Events in Trials

  • Fisetin: Across trials (AFFIRM-LITE, oncology adjunctive studies), Fisetin has shown an excellent safety profile. Even at 20 mg/kg, gastrointestinal discomfort is the only consistently reported mild side effect.
  • D+Q: The safety profile is dominated by Dasatinib. In IPF trials, adverse events included respiratory symptoms, skin rash, and anxiety. While intermittent dosing mitigates the risk of pleural effusion seen in chronic leukemia therapy, strict monitoring is maintained.

6. Safety and Toxicity Analysis

6.1 Dasatinib + Quercetin: The Risk Profile

The D+Q combination is a scalpel that must be handled with care. The toxicity is almost exclusively driven by Dasatinib.

  • Pleural Effusion: In chronic usage (CML leukemia), pleural effusion occurs in ~28% of patients. While senolytic protocols use intermittent dosing (e.g., once every 2 weeks), the cumulative risk over years of “anti-aging” therapy is unknown.
  • Acute Kidney Injury (AKI) Exacerbation: As highlighted by Battaglia-Vieni (2025), D+Q is contraindicated in acute renal injury. The interference with reparative senescence suggests that D+Q should be paused prior to elective surgeries and avoided after trauma.
  • QT Prolongation: Dasatinib can prolong the QT interval, posing a risk for arrhythmia in susceptible individuals.

6.2 Fisetin: The Safety Profile

Fisetin acts as a “soft” senolytic with a high therapeutic index.

  • NOAEL (No-Observed-Adverse-Effect Level): Toxicity studies in mice have shown no adverse effects at doses up to 2 g/kg.
  • Genotoxicity: Organometallic complexes of Fisetin and high-dose purified Fisetin have shown no mutagenic potential in Ames tests or in vivo micronucleus assays.
  • Human Tolerability: Doses up to 20 mg/kg/day (approx. 1,500 mg) are well-tolerated in clinical settings. The primary limiting factor is not toxicity, but rather the volume of powder/pills required due to low potency per milligram.
#11

And here is my standard “Claims Checking” portion of my prompt (Feel free to use it):

Part 3 Claims: Instructions

  1. Extract Claims: Identify every specific biological, medical, or protocol claim made in the transcript.

  2. Verify Externally: You must perform live searches for each claim. Do not rely on internal training data alone. Search for “[Claim] meta-analysis”, “[Claim] Cochrane review”, “[Claim] randomized controlled trial”, and “[Claim] safety profile”.

  3. Assess Hierarchy of Evidence: Evaluate the support for each claim using this strict hierarchy:

  • Level A: Human Meta-analyses / Systematic Reviews (Gold Standard).

  • Level B: Human Randomized Controlled Trials (RCTs).

  • Level C: Human Observational / Cohort Studies (Correlation, not causation).

  • Level D: Pre-clinical (Animal models, In vitro, Mechanistic speculation). Flag heavily if claim relies on this level.

  • Level E: Expert Opinion / Anecdote (Lowest quality).

  1. Search Step: For every identified claim, execute a search query formatted as: “[Topic] study [Journal Name] [Year]” (e.g., “Rapamycin lifespan study Nature 2014”).

  2. Bibliographic Verification: Before writing the response, create an internal list of the Title, Authors, Year, and DOI for each paper found.

  3. Link Validation: You must explicitly check that the domain is a trusted repository. Prioritize links containing nlm.nih.gov, doi.org, nature.com, or science.org.

  4. No Link Consensus: If a specific study cannot be found via live search, you must state “Source unverified in live search” rather than providing a placeholder or dead link.

  5. Translational Labeling: (Keep your Level A-E hierarchy, but add): For Level D (Pre-clinical), the link must explicitly point to the animal study to avoid misrepresenting it as human data.

  6. Detect Translational Uncertainty: If a claim is based on mouse/worm/yeast data but presented as human advice, label this as a “Translational Gap.”

  7. Safety Check: Explicitly search for contraindications and side effects. If safety data is missing for a specific compound/protocol, write “Safety Data Absent.”

1 Like
#12

Jay, I’m not so sure I should be used as a guide for fisetin dosing. I tend to lean to the more is better side.

I just finished this year’s protocol of 3 consecutive days each month for 5 consecutive months. I did 2,000 mg each day, which, at my weight, is 27mg per kg (not the 20mg per kg Mayo dosage). Since there may be low absorption of fisetin, I also took the pills with a little mct oil (too much mct oil and your innards might rebel). I did take it before lunch, but only because it became a habit - not much reasoning applied to that, but it could provide some additional fat on the pills.

Our AI friends have noted that fisetin requires large intermittent dosing to be effective and is not effective at all with smaller chronic dosing, so the mct oil and the extra 7mg may be beneficial. Or not. Anyway, I’m still breathing.

Like with rapamycin, I haven’t noticed anything remarkable.

1 Like
#13

This is kind of interesting. Using the free versions of ChatGPT and Grok - without subscribing, so the lowliest version of each - I got divergent answers to the same question.

When taking fenugreek and sunflower lecithin to enhance absorption of fisetin, should the lecithin and fenugreek be taken before the fisetin to prepare the stomach, so that its acid will not diminish the fisetin? If so, how much time should elapse in between taking the fenugreek and lecithin and taking the fisetin?

ChatGpt:

Short answer: no, you don’t need to “prep” the stomach first, and spacing them out doesn’t meaningfully protect fisetin from stomach acid.

Here’s the reasoning, step by step.

1. Does stomach acid significantly degrade fisetin?

Not really.
Fisetin is a flavonol that’s reasonably stable in gastric acid. The main limitation with fisetin isn’t acid destruction—it’s poor solubility and limited absorption in the intestine. So trying to neutralize or “get ahead of” stomach acid doesn’t buy you much.

2. What actually improves fisetin absorption?

  • Fat / phospholipids → helps with micelle formation in the gut
  • Bile release → stimulated by eating fat
  • Slower gastric emptying → also helped by food

Sunflower lecithin helps because it provides phosphatidylcholine, which can improve emulsification and intestinal uptake. Fenugreek is sometimes included because it may:

  • slow glucose/gastric emptying
  • mildly increase bile flow
    …but evidence for fenugreek specifically enhancing fisetin absorption is indirect and limited.

3. Should lecithin and fenugreek be taken before fisetin?

There’s no clear advantage to taking them beforehand.

  • Lecithin doesn’t need time to “coat” the stomach
  • Fenugreek doesn’t rapidly change stomach acidity in a way that protects fisetin
  • By the time fisetin reaches the small intestine (where absorption happens), everything you took together will still be present anyway

4. Timing: together vs. separated

Best practical approach:

  • Take fisetin, sunflower lecithin, and fenugreek together
  • Take them with a meal that contains some fat

If you do insist on separating them for personal preference, spacing by 10–15 minutes is plenty—but there’s no strong physiological reason to do so.

Longer gaps (30–60 minutes) don’t improve absorption and may actually reduce it if gastric emptying speeds up or bile release isn’t synchronized.

5. Practical takeaway

  • :white_check_mark: No need to “prepare” the stomach
  • :white_check_mark: No need to worry about stomach acid destroying fisetin
  • :white_check_mark: Take fisetin with lecithin and fenugreek at the same time
  • :white_check_mark: Take them with food, ideally including fat

**When taking fenugreek and sunflower lecithin to enhance absorption of fisetin, should the lecithin and fenugreek be taken before the fisetin to prepare the stomach, so that its acid will not diminish the fisetin? If so, how much time should elapse in between taking the fenugreek and lecithin and taking the fisetin?

Grok:

Yes, taking fenugreek and sunflower lecithin before fisetin can help prepare the digestive environment and potentially protect fisetin from degradation in the strongly acidic conditions of the stomach, as fisetin shows reduced stability in highly acidic pH levels. Fenugreek’s galactomannans can form a protective hydrogel-like matrix in the gut, while lecithin aids in creating micelles that enhance fisetin’s solubility and absorption. In combined formulations, these components are integrated to shield fisetin during transit through the stomach, but when taken separately, consuming fenugreek and lecithin first allows time for them to interact with the stomach environment.

Allow approximately 30 minutes to elapse between taking the fenugreek and lecithin and then taking the fisetin. This timing aligns with observations from studies on fenugreek fiber’s effects on reducing heartburn severity (similar to mild antacids) when taken 30 minutes before meals, suggesting it provides a window for the fiber to exert its mucoadhesive and protective properties. For optimal results, take fisetin with a source of healthy fats to further boost bioavailability, and consult a healthcare professional for personalized dosing, as individual responses can vary.

#14

It is interesting to see how the different LLMs respond to the same question. I took your original question and put it to Google Gemini Pro (Deep Search) - and here is what it came back with a few minutes later:

This report addresses a specific biohacking protocol: the co-administration of fenugreek galactomannan fiber and sunflower lecithin to enhance fisetin absorption. Specifically, it investigates the user-proposed hypothesis that sequential dosing—administering excipients prior to the active compound—serves to “prepare” the gastric environment against acid-induced degradation.

Comprehensive analysis of the physicochemical properties of fisetin, the rheological behavior of galactomannans, and the thermodynamics of phospholipid emulsification reveals that the hypothesis of acid degradation is chemically unfounded; fisetin is stable in gastric acid. The primary threat is acid-induced precipitation. Consequently, the optimal administration strategy relies on simultaneous co-administration rather than sequential priming. Sunflower lecithin requires direct physical proximity to fisetin to facilitate micellization, while fenugreek galactomannan serves as a gastro-retentive hydrogel scaffold.

The analysis concludes that while a brief pre-hydration period (15–30 minutes) for fenugreek may optimize gastric viscosity, the lecithin component must invariably accompany the fisetin to ensure effective solubilization. This report provides a rigorous mechanistic dissection of these interactions and proposes optimized administration protocols derived from the principles of colloidal chemistry and gastrointestinal physiology.

Infographic produced by Gemini from the same report:

Screenshot 2026-01-31 at 8.28.40 PM
Screenshot 2026-01-31 at 8.28.40 PM2844×1106 109 KB

Screenshot 2026-01-31 at 8.29.08 PM
Screenshot 2026-01-31 at 8.29.08 PM2546×986 93.8 KB

Screenshot 2026-01-31 at 8.29.35 PM
Screenshot 2026-01-31 at 8.29.35 PM2600×902 68.3 KB

And a full report:

Fisetin Absorption_ Fenugreek & Lecithin Timing.pdf (285.2 KB)

1 Like
#15

I asked the free versions for information about the ratios of the ingredients in the proprietary product and both claimed it was unavailable. Your Deep Search provided it, and without prompting, plus much more. Useful information. It’ll help me understand what I’m doing when I start my next round.

1 Like
#16

If someone else is taking fisetin using an enhanced bioavailability method, this or another, it would be interesting to hear from you.

Having just finished a round of fisetin with fenugreek and sunflower lecithin (using the convenient all-pills-all-at-once method twice and then the “gold standard” recipe set out in “Optimizing Senolytic Delivery…” [directly above this post]), I can say something definitely was happening - I was weak and stumbling around the next day. I’m fine now, so no need to bother the 911 operator.

I used 3 of he Toniiq fisetin plus quercetin pills (way less than the 10 recommended on the label for the pills alone), with fenugreek and lecithin amount each measured separately for quercetin and fisetin. While not that interested in the quercetin, I figured that since I was taking it anyway, why not take a stab at making it bioavailable.

Uncertain about the kind of oil that would be best, both for the all-pills method and the mixture, and with the notion of finding an oil without the unfortunate gastrointestinal effects of MCT oil, I asked an AI about it. For your reading pleasure, its answer is below:

My question: When attempting to emulsify sunflower lecithin powder/granules with fisetin powder/granules, what is the best oil to use? Would it be MCT, coconut, olive, or is there another oil or mixture of oils that might combine the fisetin and lecithin more thoroughly?

MCT oil is generally the best choice for emulsifying sunflower lecithin with fisetin, though coconut oil is also workable, and the specific choice depends on your intended use.

Why MCT Oil Works Best

MCT (medium-chain triglyceride) oil is ideal because it:

  • Provides a neutral medium — MCT is chemically inert and won’t interact with or degrade either lecithin or fisetin, allowing the lecithin to perform its emulsifying role without interference
  • Offers superior miscibility with lecithin — The medium-chain structure allows for better dispersion of the phospholipids without creating viscosity issues
  • Has high absorption efficiency — Both lecithin and fisetin are fat-soluble compounds, and MCT’s rapid absorption pathway means your final product will be more bioavailable
  • Won’t oxidize or degrade — MCT remains stable across a wider temperature range than unsaturated oils, protecting the fisetin (which is sensitive to oxidation)

Alternative Options

Coconut oil can work if MCT isn’t available. It’s less refined than MCT but similarly stable. Use refined (deodorized) coconut oil rather than virgin to minimize flavor interference and reduce the risk of oxidation.

Avoid olive oil — While high-quality olive oil is healthy, it’s too oxidation-prone for fisetin, which degrades relatively quickly when exposed to oxygen and light. The polyphenols in olive oil might also interfere with lecithin’s emulsifying efficiency.

Practical Approach

A combination of MCT with a small amount (5–15%) of sunflower oil can work well, as it provides:

  • The stability and emulsifying efficiency of MCT as the base
  • Additional fat-soluble nutrient carriers from sunflower oil
  • Improved absorption profile

The lecithin itself is your emulsifier, so your primary goal is choosing an oil that stays stable and doesn’t compete with the lecithin’s amphipathic structure. MCT accomplishes this best.

My question: What would be the smallest amount of MCT oil to use for each gram of the combined (fisetin and sunflower lecithin powder/granules) dry mixture that would still be optimum?

Approximately 15:1 to 20:1 (by weight/volume) is the optimal minimum ratio — meaning 15–20 ml of MCT oil per 1 gram of your combined dry powder mixture.

How This Ratio Works

At this concentration range, sunflower lecithin achieves critical micelle concentration (CMC) — the minimum amount needed to effectively coat and disperse particles. Here’s the logic:

  • Too little oil (< 10:1): The lecithin can’t properly hydrate or form a complete emulsion network. Particles will clump, and fisetin remains poorly dispersed.
  • 15–20:1 sweet spot: Lecithin molecules have enough oil to properly orient themselves (hydrophilic heads outward, lipophilic tails in), creating a stable colloidal suspension with minimal excess oil.
  • More oil (20:1+): Additional emulsification benefits diminish, and you’re mostly adding extra bulk without improving bioavailability or dispersion.

Practical Considerations

The exact ratio depends on:

  • Lecithin concentration in your dry mix — If your blend is 40% lecithin and 60% fisetin, you need slightly less oil than if it’s 20% lecithin. Higher lecithin content means better emulsification at lower oil volumes.
  • Particle size of your powders — Finer granules require less oil; coarser ones may need 20:1 or slightly higher.
  • Intended final use — If this is for a liquid supplement, 15:1 works well. If you’re trying to create a paste or semi-solid, you might stay closer to 15:1. If you want a free-flowing suspension, 20:1 is safer.

Start conservatively at 15:1 and increase to 20:1 if you observe clumping during mixing. This gives you the leanest formulation while maintaining stability.

My question: Between refined coconut oil and sunflower oil, which would be best, and would its superiority be significant?

Refined coconut oil is significantly better than sunflower oil for this application — and the difference matters.

Why Refined Coconut Oil Wins

Refined coconut oil (the deodorized kind):

  • Much more oxidation-resistant — It’s predominantly saturated fat, so it resists rancidity and oxidative breakdown, which directly protects your fisetin from degradation
  • Chemically closer to MCT — Refined coconut oil contains a meaningful proportion of medium-chain fatty acids, giving it similar emulsification and absorption characteristics to MCT oil itself
  • Stable long-term — Your final product will maintain potency over weeks or months; fisetin won’t degrade as quickly
  • Better lecithin performance — The saturated fat structure doesn’t interfere with phospholipid orientation the way polyunsaturated oils can

Sunflower oil, by contrast:

  • High in linoleic acid (polyunsaturated fat) — This is oxidation-prone, especially with light and heat exposure
  • Incompatible with fisetin stability — Fisetin is a polyphenolic compound sensitive to oxidative stress. Sunflower oil’s susceptibility to rancidity creates an environment where fisetin degrades faster
  • Shorter shelf life — You’d see degradation within weeks

Significance of the Difference

Yes, this is significant — not marginal. If you use sunflower oil, you could lose 20–40% of your fisetin’s potency within 4–8 weeks, depending on storage conditions. With refined coconut oil, you’d retain 85–95% over the same period.

Use refined coconut oil as your fallback when MCT isn’t available. It’s a legitimate second choice, whereas sunflower oil would work against your formulation’s stability.

My question: Of all the oils readily available from common retail sources, are there any others that would be equal to or better than MCT oil or refined coconut oil?

No, there aren’t any commonly available retail oils that would be better than MCT oil or refined coconut oil for this specific application. However, there are two that come reasonably close:
Near-Equivalent Options
High-oleic sunflower oil (also called NuSun or high-oleic varieties):
• Contains 75%+ oleic acid (monounsaturated fat) instead of the 60% linoleic acid (polyunsaturated) in regular sunflower oil
• Significantly more oxidation-resistant than standard sunflower oil
• Still not quite as stable as refined coconut oil, but considerably better — you’d retain ~85% fisetin potency over 8 weeks instead of 60%
• Readily available at most retailers
Macadamia nut oil:
• Highest in monounsaturated fats (~80%) among common retail oils
• Naturally resistant to oxidation due to its fatty acid profile
• Contains native antioxidants that further protect the fisetin
• Could be roughly equal to refined coconut oil in performance
• Less widely available but increasingly found at mainstream stores
Why Nothing Beats MCT/Coconut
Both alternatives have downsides compared to your top two choices:
• They lack MCT’s rapid absorption characteristics
• They don’t have the medium-chain fatty acid advantage of refined coconut
• Macadamia oil is significantly more expensive
• High-oleic sunflower oil, while improved, still has slightly higher oxidation risk
Bottom line: MCT is optimal, refined coconut oil is the best fallback, and high-oleic sunflower oil or macadamia nut oil are acceptable third choices — but the difference between refined coconut and these alternatives is noticeable enough that I wouldn’t recommend them unless you specifically couldn’t obtain the first two.

2 Likes
#17

Well … the AI assumed I was making the mixture for storage. The information it gave will be valuable for that case. But it turns out that ingesting it immediately after mixing is a different story.

MY question: When combining fisetin and sunflower lecithin with oil and storing for later use, MCT oil or refined coconut oil are the best. But when ingesting the mixture immediately after combining it, would olive oil, peanut oil, sunflower oil, or any other oil be just as effective?

You’ve identified an important distinction. Yes, when consuming the mixture immediately, olive oil, peanut oil, sunflower oil, and other oils should be effectively equivalent for bioavailability purposes.

Here’s why the oils differ based on timing rather than inherent effectiveness:

Storage vs. Immediate Consumption

Why MCT and refined coconut oil excel for storage:

  • Oxidation resistance: These oils are highly saturated, making them much slower to oxidize and go rancid. Over weeks or months, this matters significantly.
  • Shelf stability: Refined coconut oil and MCT oil have far longer stable shelf lives than unsaturated oils like olive, sunflower, or peanut oil.

Why this matters less for immediate consumption:

  • No oxidation yet: If you’re consuming the mixture within minutes or hours of combining, the oil hasn’t had time to oxidize, so the stability advantage of MCT/coconut oil disappears.
  • Fat-solubility is what counts: Both fisetin and lecithin are fat-soluble compounds, and they dissolve reasonably well in any oil. The type of oil matters far less than the presence of some fat to facilitate absorption.

Practical Takeaway

For immediate consumption, olive oil, peanut oil, sunflower oil, and other common oils should work just as effectively as MCT or refined coconut oil because you’re capturing the absorption benefit (the fat carrier) without needing the oxidation resistance that storage requires.

If you were storing the mixture for several weeks, the oxidation sensitivity of unsaturated oils would become a real concern—the fisetin and lecithin compounds could degrade alongside rancid oil.

#18

And I continue to beat this dead mouse.

My earlier question was: When attempting to emulsify sunflower lecithin powder/granules with fisetin powder/granules, what is the best oil to use? Would it be MCT, coconut, olive, or is there another oil or mixture of oils that might combine the fisetin and lecithin more thoroughly? The answer I was looking for was which oil would best combine in a way that each powder/granule molecule is bound with an oil molecule.

I understand you’re looking for the oil that would create the most complete and thorough binding between the lecithin and fisetin molecules, rather than just creating a stable mixture.

For your specific goal of maximizing molecular-level binding, MCT oil is likely your best choice, followed by a coconut/MCT blend. Here’s why:

Oil Selection for Optimal Molecular Binding

MCT oil performs best because:

  • It has optimal viscosity and polarity that works synergistically with lecithin’s emulsifying structure
  • MCT’s medium-chain length allows lecithin molecules to orient themselves effectively around both the oil and fisetin particles
  • It has the least interference from competing compounds (unlike olive oil’s polyphenols)
  • Its lower melting point aids in better dispersion and contact between molecules during mixing

Why the alternatives fall short:

  • Coconut oil is more saturated and can solidify, reducing molecular mobility and contact points at room temperature
  • Olive oil contains polyphenols that compete with fisetin for lecithin’s binding sites and can interfere with optimal emulsion structure
  • Single oils may not provide enough molecular flexibility for complete coverage

Recommended Approach

For maximum molecular binding efficiency:

  1. MCT oil alone (if stability and fluidity at room temperature matter)
  2. MCT/coconut blend (70/30 or 80/20) - coconut adds some additional binding leverage from its fatty acid profile while MCT maintains fluidity
  3. Use gentle heating and prolonged mixing to ensure maximum surface contact between all three components

The key is that lecithin needs room to spread its hydrophobic and hydrophilic ends around both the oil and fisetin particles—MCT’s molecular properties create the optimal environment for this orientation.

1 Like
#19

The fisetin story seems to have been based on a huge error:

#20

Fisetin 1200mg Liposomal Fisetin is a commercial product.

One of the products:

#21

@argonaut , I just re-read your posts, and it seems like we’ve had similar thoughts and similar results from Grok and Gemini. I wonder what other supplements this might work for… so I’ve created this thread , starting with Urolithin A: DIY: inexpensive workarounds to significantly enhance the bioavailability of lipophilic compounds like Urolithin A at home

There may be easy ways to make DYI solutions that are similar to the liposomal formulations but much less expensive. See this query I did on urolithin A, (see second section below). Perhaps someone here with more experience in this are can dig deeper on this issue. (

from Gemini

The short answer is no, there are no authentic, high-efficiency “DIY” methods to produce true nano-micronized or nano-liposomal delivery systems at home using basic kitchen tools. The popular internet protocols—primarily using jewelry ultrasonic cleaning baths and soy lecithin—produce coarse macro-emulsions rather than true lipid-encapsulated nanoparticles.

However, there are highly practical, inexpensive chemical workarounds to significantly enhance the bioavailability of lipophilic compounds like Urolithin A (UA) at home without industrial equipment.

The Mechanical and Thermodynamic Bottlenecks of DIY Formulations

1. The Acoustic Energy Gap (Vesicle Size Failure)

To achieve the rapid cell-membrane fusion and lymphatic bypass associated with modern lipid delivery, liposomes must be Small Unilamellar Vesicles (SUVs) with a particle size between 20 nm and 200 nm.

  • The Reality of Ultrasonic Baths: Standard ultrasonic jewelry cleaners operate at low frequencies (35–40 kHz) and low power densities, distributed over a large water volume. Particle size distribution (PSD) analysis shows that bath sonication fails to disrupt large multilamellar vesicles (MLVs), resulting in particles consistently greater than 500–1,000 nm.
  • The Industrial Standard: True nano-encapsulation requires laboratory-grade probe sonicators or high-pressure microfluidizers that deliver concentrated acoustic cavitation directly into a small volume to violently shear lipid sheets into nanometer-scale spheres.

2. The Hydrophobic Loading Problem

Most online DIY liposome recipes are designed for hydrophilic (water-soluble) molecules like Vitamin C, which easily dissolve in the aqueous core of a lipid vesicle.

  • Urolithin A is highly lipophilic (hydrophobic). It has virtually zero aqueous solubility but dissolves in organic solvents (DMSO, DMF, absolute ethanol) and certain lipid phases.
  • If you simply mix raw UA powder, water, and lecithin into an ultrasonic bath, the UA crystals will remain un-encapsulated, suspended loosely in the water or clumped as an unstable macro-emulsion, providing zero kinetic or pharmacokinetic advantage.

Pragmatic, High-Bioavailability DIY Workarounds

To bypass the need for industrial nanotech, you can exploit the lipophilic nature of the compound by creating a Simplified Self-Emulsifying Drug Delivery System (SEDDS) or utilizing mechanical wet-milling.

1. The SEDDS Lipid Carrier Proxy (Highest Efficiency)

Instead of trying to force a liposome to form in water, dissolve the compound directly into a lipid matrix that the human digestive tract absorbs via the lymphatic system (bypassing first-pass liver metabolism). Preclinical data indicates that submicron oil-in-water emulsions drastically improve UA baseline bioavailability.

  • The Carrier: Medium-Chain Triglyceride (MCT) oil or high-oleic sunflower oil.
  • The Emulsifier/Surfactant: Liquid sunflower lecithin or food-grade Polysorbate 80 (Tween 80).
  • The Protocol:
    1. Warm a measured volume of MCT oil gently (approx. 50–60°C / 122–140°F). Do not overheat, as polyphenols can degrade.
    2. Add the raw Urolithin A powder alongside 10–20% liquid lecithin by volume.
    3. Agitate vigorously (using a high-shear laboratory stirrer or a high-speed milk frother) until the crystalline powder is fully solubilized or uniformly suspended in the lipid phase.
  • Why it works: When this lipid mixture hits gastric fluids and bile salts, it spontaneously forms crude micellar structures and micro-emulsions in the gut, mimicking commercial lipid-encapsulation mechanics.

2. Low-Cost Wet Milling (Mechanical Micronization)

If you prefer a solid or powder format, you can manually reduce particle size to increase surface area, which accelerates the dissolution rate in the intestine.

  • The Protocol: Place the raw compound into a ceramic mortar and pestle. Add a few drops of absolute ethanol (99% food-grade) and a small amount of powdered lecithin to create a thick paste. Grind aggressively for 15–20 minutes as the solvent evaporates.
  • Why it works: The shear force mechanically breaks down larger crystalline aggregates (micronization), while the amphiphilic lecithin coats the newly sheared micro-crystals, preventing re-agglomeration and improving wettability when it enters the gastrointestinal tract.

Knowledge Gaps & Uncertainties

While these lipid-carrier and wet-milling methods optimize the kinetic environment for absorption, the exact peak serum concentration (C_{max}) and Area Under the Curve (AUC) achieved via home preparation remain unquantified. Without analytical validation tools like Dynamic Light Scattering (DLS) or High-Performance Liquid Chromatography (HPLC), the exact percentage of compound successfully solubilized or micronized vs. what remains unabsorbed can only be estimated based on broad pharmaceutical principles.

#22

And, I asked it using the SEDDS approach with Fisetin:

The SEDDS Lipid Carrier Proxy method works exceptionally well with Fisetin. Due to its specific physicochemical properties, Fisetin is an even more critical candidate for lipid-based delivery strategies than Urolithin A.

Physicochemical Rationale for Fisetin

Fisetin (3,3′,4′,7-tetrahydroxyflavone) faces severe pharmacokinetic bottlenecks when ingested as a raw crystalline powder. Its delivery challenges stem from three main barriers:

ResearchGate

  • High Lipophilicity and Low Solubility: Fisetin has a partition coefficient (logP≈3.2) indicating high fat-solubility, but its aqueous solubility is extremely low at approximately 10.45 μg/mL. It cannot dissolve efficiently in the aqueous environment of the gastrointestinal tract.

PMC - NIH

  • Aggressive First-Pass Metabolism: Once in the intestine, Fisetin is rapidly metabolized by UDP-glucuronosyltransferases (UGTs) and sulfotransferases in both the gut wall and the liver. This converts free Fisetin into glucuronide and sulfate conjugates, significantly lowering its systemic potency.

PMC - NIH

  • Efflux Transporter Clearance: Fisetin is a known substrate for P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) efflux pumps, which actively pump the absorbed molecule out of enterocytes and back into the intestinal lumen.

PMC - NIH

Expected Bioavailability Multipliers

Peer-reviewed pharmacokinetic data evaluating self-emulsifying and lipid-nanoemulsion systems for Fisetin demonstrates massive absorption advantages over standard unformulated powder:

Formulation Type Bioavailability Increase (AUC) Cmax Increase Primary Mechanism Source
Liquid SEDDS / SNEDDS 6.86-fold ~5-fold Complete crystalline dissolution; surfactant-mediated mucosal permeation Gunjal et al., 2024
Self-Emulsified Micellar Hydrogel 26.9-fold 23.8-fold Maximum systemic exposure; protection against enterocyte degradation Joseph et al., 2022
Lipid Nanoemulsion (IP/Oral proxy) 24-fold Variable Direct lymphatic transport; evasion of hepatic clearance Ragelle et al., 2012

Why the Proxy Method is Highly Effective for Fisetin

When Fisetin is pre-dissolving into a mixture of Medium-Chain Triglyceride (MCT) oil and a phospholipid surfactant like sunflower lecithin, it alters the pharmacokinetic pathway in two ways:

1. P-gp Efflux Transporter Inhibition

Phospholipids and lipid degradation products naturally act as mild, non-toxic inhibitors of P-gp and BCRP efflux pumps in the brush border membrane. By co-administering Fisetin within a dense lipid-surfactant matrix, you temporarily saturate or inhibit these efflux pumps, allowing a higher percentage of free Fisetin to cross into the bloodstream.

2. Intestinal Lymphatic Targeting

The long-chain and medium-chain fatty acids in the carrier stimulate the secretion of chylomicroons by the enterocytes. Highly lipophilic molecules (logP>3) dissolve into these chylomicrons and enter the lymphatic system via the lacteals. Because the lymphatic system empties directly into the systemic circulation via the thoracic duct, a portion of the Fisetin completely bypasses the portal vein and avoids initial first-pass hepatic glucuronidation.

Practical Formulating Caveat for DIY Fisetin SEDDS

Fisetin possesses a highly stable crystalline lattice with strong intermolecular hydrogen bonding, giving it a high melting point (~330°C). This makes it significantly more stubborn to dissolve in pure oils than Urolithin A.

To achieve complete solubilization in a DIY setting, the oil matrix must be held at 55–60°C (131–140°F) during mixing, and the ratio of surfactant (lecithin) must be increased to roughly 20–25% of the total lipid volume to serve as a co-solvent. If the mixture appears cloudy or exhibits sediment upon cooling, the Fisetin has recrystallized, which will reduce the expected bioavailability multiplier back toward baseline.